For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 491,134 | 3,813,703.5* | 1,517,723 | 2,167,114 |
| General and administrative | 1,668,454 | 5,361,934.5* | 1,130,764 | 2,289,649 |
| Total operating expenses | 2,159,588 | 9,175,638 | 2,648,487 | 4,456,763 |
| Loss from operations | -2,159,588 | -9,175,638* | -2,648,487 | -4,456,763 |
| Warrant repricing | 410,154 | - | - | - |
| Other income, net | 28,672 | 56,065.5* | 39,088 | 15,547 |
| Change in fair value of convertible promissory notes | - | 576,710.5* | -365,718 | -787,703 |
| Total other income (expense), net | -381,482 | - | - | - |
| Net loss | -2,541,070 | -8,542,862 | -2,975,117 | -5,228,919 |
| Basic EPS | -0.23 | -8.842 | -2.98 | -9.09 |
| Diluted EPS | -0.23 | -8.842 | -2.98 | -9.09 |
| Basic Average Shares | 10,956,650 | 966,124* | 997,038 | 574,923 |
| Diluted Average Shares | 10,956,650 | 966,124* | 997,038 | 574,923 |